AP&T: Editors' Declarations of Interest

Professor C. W. Howden, Editor

Professor Howden is a consultant/speaker for Phathom Pharmaceuticals, consultant/speaker for RedHill Biopharma, consultant/speaker for Meridian Diagnostics, and consultant for Sebela/Braintree. He owns stock in Antibe Therapeutics and has stock options in EndoStim.

Professor R. Loomba, Editor

Professor Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals, and Viking Therapeutics. He has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes, and Terns Pharmaceuticals. He is also the co-founder of LipoNexus Inc.

Professor A. C. Ford, Associate Editor

Professor Ford has received grant/research support from GE Healthcare and Tillotts Pharma, and acted as a consultant/speaker for Dr. Falk, GE Healthcare, Sandoz, and Takeda Pharmaceuticals.

Professor G. M. Dusheiko, Associate Editor

Professor Dusheiko serves on independent data safety monitoring boards for Aligos, Arbutus, Glaxo Smith Kline, Janssen, Gilead, Precision Biosciences and Tune. In the past 2 years, he has received honoraria from Arbutus, Antios, Aligos and Gilead Sciences and he serves as an advisor to the National Medical Research Council, Singapore, the TherVacB Consortium (European Horizon Grant) and the A-Tango Consortium (EUH2020 grant).

Professor G. L.-H. Wong, Associate Editor

Professor Wong has served as an advisory committee member for AstraZeneca, Gilead Sciences, GlaxoSmithKline, Janssen, and Virion Biotherapeutics, and as a speaker for Abbott, AbbVie, Ascletis Pharmaceuticals, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen, and Roche, and received research grants from Gilead Sciences.

Professor R. B. Gearry, Associate Editor

Professor Gearry is, or has been, a member of advisory boards for AbbVie, Janssen, Schering-Plough, Zespri, Baxter, and Celltrion. He has received honoraria or travel grants from AbbVie, Janssen, Schering-Plough, Zespri, Ferring, and Celltrion. He has received research grants for investigator-initiated studies from AbbVie, Janssen, Goodman-Fielder, Comvita, and Zespri.

Professor C. H. Seow, Associate Editor

Professor Seow is a member of advisory boards for Abbvie, Amgen, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, Lilly, Pfizer, Pharmascience, Sandoz, Sanofi, Shire, and Takeda and has been a speaker for Abbvie, Fresenius Kabi, Janssen, Lilly, Ferring, Organon, Pfizer, Pharmascience, Shire, and Takeda.

Dr S. Subramanian, Associate Editor

Dr. Subramanian is/has been on the speaker bureau for Abbvie, Bristol-Myers Squibb, Celltrion, Dr. Falk Pharmaceuticals, Lilly, Ipsen, Janssen, Eisat and Takeda, and received educational grants from Abbvie, Janssen and Takeda and is/has been an advisory board member for Abbvie, Celltrion, Dr. Falk Pharmaceuticals, Janssen, Takeda and Vifor Pharmaceuticals.

Professor J. A Tye-Din, Associate Editor

Professor Tye-Din has privately, or via his institute, been a consultant or advisory board member for Anatara, Anokion, Barinthus Biotherapeutics, Chugai Pharmaceuticals, Dr. Falk, EVOQ Therapeutics, Equillium, Forte Biosciences, IM Therapeutics, Janssen, Kallyope, Mozart Therapeutics, Takeda, TEVA, and Topas. He has received research funding from Barinthus Biotherapeutics, Chugai Pharmaceuticals, Codexis, DBV Technologies, EVOQ Therapeutics, Immunic, Kallyope, Novoviah Pharmaceuticals, Topas, and Tillotts Pharmaceuticals. He is an inventor on patents relating to the use of gluten peptides in coeliac disease diagnosis and treatment.

Dr P. J Trivedi, Associate Editor

Dr. Trivedi receives institutional funding support from the National Institute of Health and Social Care Research (NIHR) Birmingham. He has also received lecture fees from Advanz/Intercept, Albireo/Ipsen, Dr. Falk Pharma, Perspectum Ltd. and Zambon. He has received consulting fees from Advanz/Intercept, Albireo/Ipsen, ChemoMab, Cymabay/Gilead, Dr. Falk, GSK, Kowa, Mirum and Pliant; and grant support from Bristol Myers Squibb, Core (Guts United Kingdom), EASL, Gilead Sciences, GSK, Intercept, Ipsen, LifeArc, Medical Research Foundation (United Kingdom), Mirum, NIHR, PSC Support, Regeneron and The Wellcome Trust.

Dr D. Q. Huang, Associate Editor

Dr. Huang has served as an advisory board member for Gilead and Roche.

Professor R. E. Pounder, Founding Editor 1987–2017; Emeritus Editor and Advisor 2018 to present.

None to declare.

Policy

If an editor has a potential conflict of interest with the contents of a manuscript, usually that manuscript will be transferred to another editor. Occasionally, because of the specialist nature of some manuscripts and limited experience of the other editors, the manuscript may remain under the supervision of the original specialist editor, who will confer with other editors before making a decision.

06 May 2025